NEW YORK, NY / ACCESSWIRE / January 7, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Baxter International Inc. (BAX)
Class Period: February 21, 2019 to October 23, 2019
Lead Plaintiff Deadline: January 24, 2020

During the class period, Baxter International Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

Learn about your recoverable losses in BAX: http://www.kleinstocklaw.com/pslra-1/baxter-international-inc-loss-submission-form?id=5197&from=1

Merit Medical Systems, Inc. (MMSI)
Class Period: February 26, 2019 to October 30, 2019
Lead Plaintiff Deadline: February 3, 2020

The MMSI lawsuit alleges that throughout the class period, Merit Medical Systems, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

Learn about your recoverable losses in MMSI: http://www.kleinstocklaw.com/pslra-1/merit-medical-systems-inc-loss-submission-form?id=5197&from=1